Advertisement

Molecular Diagnosis & Therapy

, Volume 22, Issue 4, pp 503–504 | Cite as

Comment on “Targeting AMPK, mTOR and β-Catenin by Combined Metformin and Aspirin Therapy in HCC: An Appraisal in Egyptian HCC Patients”

  • Go J. Yoshida
Letter to the Editor
  • 48 Downloads

Abdelmonsif et al. [1] have recently reported that hepatocellular carcinoma (HCC) tends to exhibit higher levels of phosphorylated AMP-activated protein kinase (AMPK), phosphorylated mammalian target of rapamycin (mTOR), and β-catenin expression than pre-malignant conditions of cirrhosis. Notably, the combination of metformin and aspirin shows anti-tumor effect in HepG2 cells, with decreased levels of mTOR/AMPK and Wnt/β-catenin signal pathways. Given that metformin has been used for the treatment of type 2 diabetes mellitus and aspirin is one of the non-steroidal anti-inflammatory drugs (NSAIDs), this research holds much promise in terms of drug repositioning (DR) [1, 2]. Terfenadine, a histamine H1receptor antagonist, has been used for a long period to treat autoimmune disorders such as allergic dermatitis. In a typical DR therapeutic strategy, terfenadine suppresses the invasive and metastatic potentials of malignant melanoma. Mechanistically, terfenadine induces reactive oxygen...

Notes

Compliance with Ethical Standards

Funding

This letter did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Conflict of interest

GY has no potential conflict of interest relevant to this letter to report.

References

  1. 1.
    Abdelmonsif DA, Sultan AS, El-Hadidy WF, Abdallah DM. Targeting AMPK, mTOR and β-catenin by combined metformin and aspirin therapy in HCC: an appraisal in Egyptian HCC patients. Mol Diagn Ther. 2018;22(1):115–27.CrossRefPubMedGoogle Scholar
  2. 2.
    Yoshida GJ. Therapeutic strategies of drug repositioning targeting autophagy to induce cancer cell death: from pathophysiology to treatment. J Hematol Oncol. 2017;10(1):67.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Jeong HJ, Oh HA, Nam SY, Han NR, Kim YS, Kim JH, et al. The critical role of mast cell-derived hypoxia-inducible factor-1α in human and mice melanoma growth. Int J Cancer. 2013;132(11):2492–501.CrossRefPubMedGoogle Scholar
  4. 4.
    Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149(5):1060–72.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Lu B, Chen XB, Ying MD, He QJ, Cao J, Yang B. The role of ferroptosis in cancer development and treatment response. Front Pharmacol. 2018;8:992.CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Tewari D, Majumdar D, Vallabhaneni S, Bera AK. Aspirin induces cell death by directly modulating mitochondrial voltage-dependent anion channel (VDAC). Sci Rep. 2017;7:45184.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Moon RT, Kohn AD, De Ferrari GV, Kaykas A. WNT and beta-catenin signalling: diseases and therapies. Nat Rev Genet. 2004;5(9):691–701.CrossRefPubMedGoogle Scholar
  8. 8.
    Stacey DW. Cyclin D1 serves as a cell cycle regulatory switch in actively proliferating cells. Curr Opin Cell Biol. 2003;15(2):158–63.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Pathological Cell Biology, Medical Research InstituteTokyo Medical and Dental UniversityTokyoJapan

Personalised recommendations